| DRUG WATCH |
|
| Year : 2016 | Volume
: 48
| Issue : 3 | Page : 316-317 |
Atypical post-finasteride syndrome: A pharmacological riddle
Anita K Gupta, Neetu Sharma, Prashant Shukla
Department of Pharmacology, Government Medical College, Patiala, Punjab, India
Correspondence Address:
Dr. Neetu Sharma
Department of Pharmacology, Government Medical College, Patiala, Punjab
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.182898
Finasteride and dutasteride are commonly used 5-alpha reductase inhibitors. While finasteride is a selective inhibitor of 5-alpha reductase Type II, dutasteride inhibits 5- alpha reductase Type I and II. The United States Food and Drug Administration approved the use of finasteride for benign prostatic hypertrophy (BPH) as well as androgenic alopecia (AGA) while dutasteride is approved only for BPH. Off-label use of dutasteride is not uncommon in AGA as well. Although the postfinasteride syndrome (PFS) is a well-established entity, its symptomatology is quite variable. Here, we describe a case of an atypical PFS in a patient treated with dutasteride and finasteride for AGA. The multisystem involvement and irreversible nature of this case warrant its reporting.
[FULL TEXT] [PDF]*
|
